Merlin Biotech, Inc.
Monday, February 26, 2024
Uris
Oncology
MERLIN Biotech is a pre-clinical stage mRNA platform company with a novel 1st in class cancer immunotherapy with exclusive IP in major worldwide markets. Our target, USP6, has demonstrated invivo efficacy with supporting human epidemiological survival data. These data support a broad cancer indication with an adult market estimated 5 year sales at $2 billion
State
PA
Country
United States
Website
http://www.merlinbiotech.com
CEO/Top Company Official
Randall N. Hyer, MD, PhD, MPH
Lead Product in Development
MER-101, an mRNA delivered novel immunostimulatory protein with human epidemiological data showing a survival benefit in numerous solid cancers.
Development Phase of Primary Product
Pre-Clinical
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}